Nuwellis (NASDAQ:NUWE – Get Free Report) released its earnings results on Tuesday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.24), Zacks reports. Nuwellis had a negative net margin of 169.54% and a negative return on equity of 28,159.25%. The firm had revenue of $1.90 million during the quarter, compared to the consensus estimate of $2.50 million.
Nuwellis Stock Down 3.5%
Nuwellis stock opened at $0.96 on Thursday. The firm has a fifty day simple moving average of $0.99 and a two-hundred day simple moving average of $1.20. Nuwellis has a twelve month low of $0.75 and a twelve month high of $11.66. The company has a market capitalization of $4.22 million, a PE ratio of -0.01 and a beta of 0.51.
Analyst Upgrades and Downgrades
Separately, Roth Capital reaffirmed a “buy” rating on shares of Nuwellis in a research note on Tuesday.
Nuwellis Company Profile
Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Further Reading
- Five stocks we like better than Nuwellis
- How to Calculate Options Profits
- 2 High Growth Buy Now, Pay Later Stocks Challenging PayPal
- Health Care Stocks Explained: Why You Might Want to Invest
- Analysts Say Unilever Has the Leverage to Hit New Highs
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Homebuilders: Oversold, Undervalued, and Ready to Run?
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
